(Alprazolam)
Alpragen and Alprazolam Viatris 1 mg tablets EFG are different trade names for the same medicine.
Alpragen contains the active substance alprazolam, which belongs to a group of medicines called benzodiazepines.
Alpragen is indicated for the treatment of symptoms of anxiety disorders in adults, only in situations where the symptoms are severe, prevent normal functioning, or are very troublesome for the patient. This medicine is intended for short-term use only.
Before starting to take Alpragen, you should discuss it with your doctor or pharmacist
During treatment with Alpragen, the patient may experience anterograde amnesia. To reduce the risk, the patient should have uninterrupted sleep for 7-8 hours during treatment.
Treatment with alprazolam has been associated with unusual reactions, such as: anxiety, especially motor, excitement, irritability, aggression, delusions, outbursts of anger, nightmares, hallucinations (seeing or hearing things that do not exist), psychosis (loss of contact with reality) and strange behavior. If such symptoms occur, you should consult a doctor,
as it may be necessary to stop taking the medicine.
Taking Alpragen is not recommended for children and adolescents under 18 years of age.
You should tell your doctor or pharmacist about all medicines you are taking, have recently taken, or plan to take, including those that are available without a prescription. It is especially important to inform your doctor about taking medicines such as:
Taking Alpragen with opioids (strong painkillers, medicines used in substitution therapy for opioid addiction, some antitussive medicines) increases the risk of drowsiness, breathing difficulties (respiratory depression), coma, and can be life-threatening.
Deaths have been reported. For this reason, concurrent use should only be considered when other treatment methods are not possible.
However, if the doctor prescribes Alpragen with opioids, the dosage and duration of such treatment should be limited by the attending physician.
You should inform your doctor about all opioid medicines you are taking and strictly follow the dosage prescribed by your doctor. It may be helpful to inform friends or family about the above symptoms. If such symptoms occur, you should contact your doctor.
In case of planned surgery under general anesthesia, you should inform your doctor about taking alprazolam.
You should not drink alcohol while taking Alpragen; alcohol enhances the effect of Alpragen.
You should not drink too much grapefruit juice while taking this medicine, as it may increase the amount of alprazolam in the blood.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult a doctor or pharmacist before taking this medicine. Alpragen should not be taken
if the patient is pregnant without discussing the possible risks and benefits of taking this medicine with their doctor.
If alprazolam is taken regularly in the last trimester of pregnancy, the baby may experience dependence on alprazolam and withdrawal symptoms after birth.
If the doctor decides to take alprazolam in late pregnancy or during childbirth, the baby may experience symptoms such as low body temperature, limpness, breathing difficulties, and feeding difficulties, tremors, increased irritability, and excitement.
Alpragen should not be taken during breastfeeding, as the medicine may pass into breast milk.
You should not drive vehicles or operate machinery after taking alprazolam, as symptoms such as loss of concentration, loss of muscle control, memory loss, dizziness, drowsiness, or confusion may occur.
If the patient has previously been diagnosed with intolerance to some sugars, they should consult their doctor before taking Alpragen.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means the medicine is considered "sodium-free".
This medicine contains 0.1 mg of sodium benzoate in each tablet.
Sodium benzoate may increase the risk of jaundice (yellowing of the skin and whites of the eyes) in newborns (up to 4 weeks of age), but this medicine is not recommended for use in patients under 18 years of age.
This medicine should always be taken according to the doctor's or pharmacist's instructions. If you have any doubts, you should consult a doctor or pharmacist.
Alpragen is available in doses of 0.25 mg, 0.5 mg, and 1 mg.
The recommended dose is 0.25 mg to 0.5 mg three times a day.
If necessary, the doctor may decide to increase the dose to a maximum of 4 mg per day. In case of doubts, you should consult your doctor or pharmacist again.
Care should be taken when increasing the dose. The evening dose should be increased first, and then the daytime dose.
Lower doses should be used in patients who have not taken this type of medicine before and in patients with a history of alcohol dependence.
The recommended dose for elderly patients is 0.25 mg two to three times a day. In elderly patients in good physical condition, the doctor may increase the dose by 0.5 mg every third day, up to a maximum dose of 1.5 mg per day. In frail elderly patients, the dose should not exceed 0.75 mg per day.
Alpragen should be taken orally. The score line on the tablet is only to facilitate breaking the tablet to make it easier to swallow.
In case of liver or kidney failure, the doctor may recommend a lower dose than usual. The maximum recommended dose for patients with liver or kidney failure is 0.75 mg to 1.5 mg per day.
Alpragen should not be taken for longer than prescribed by the doctor. The total treatment duration should not be longer than 2-4 weeks. Taking alprazolam for too long and in too high a dose may lead to the development of psychological and physical dependence. Treatment should not be stopped prematurely.
In case of taking a higher dose than recommended, you should immediately consult a doctor or go to the emergency department of the nearest hospital. You should take the packaging of the medicine and any remaining tablets with you. Symptoms of overdose include: drowsiness, confusion, lack of coordination or uncertain movements, breathing difficulties, low blood pressure, fatigue, loss of consciousness, and in rare cases, death.
You should not take a double dose to make up for a missed dose; you should only take the next dose at the right time.
You should not stop taking Alpragen on your own. Before stopping treatment, the doses of the medicine should be gradually reduced. The doctor will inform you how to do this. If you stop taking Alpragen or stop treatment too early, you may experience symptoms such as: anxiety, restlessness, especially motor, seizures, headaches, muscle pain, tension, confusion, irritability, involuntary movements, and difficulty sleeping. In extreme cases, symptoms may also include loss of consciousness, loss of contact with reality, increased sensitivity to light, sound, and touch, feeling of numbness or tingling in the limbs, seeing or hearing things that do not exist, seizures, abdominal cramps, and muscle spasms, vomiting, sweating, and trembling.
If you have any further doubts about taking this medicine, you should consult a doctor or pharmacist.
Like all medicines, Alpragen can cause side effects, although not everybody gets them.
In people with a history of violence, borderline personality disorders, alcohol abuse, and people taking medicines that affect the central nervous system, hostile or aggressive behavior has been observed. If the patient has post-traumatic stress disorder, stopping treatment with Alpragen may cause irritability, hostility, and unpleasant thoughts and reflections.
Common side effects are usually observed at the beginning of treatment with Alpragen. These symptoms usually disappear during further treatment.
You should immediately inform your doctorif you experience any of the following side effects, as they may be serious:
Uncommon(may affect up to 1 in 100 people)
Side effects with unknown frequency(frequency cannot be estimated from available data)
You should stop taking the medicine. The doctor will inform you how to do this.
Other side effects
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Side effects with unknown frequency(frequency cannot be estimated from available data)
If you experience any side effects, including any side effects not listed in this leaflet, you should tell your doctor, pharmacist, or nurse.
Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
tel.: +48 22 49 21 301
fax: + 48 22 49 21 309
website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help gather more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Do not store above 25°C. Store in the original packaging to protect from light.
Do not take this medicine after the expiry date stated on the packaging.The expiry date refers to the last day of the specified month.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
1 mg tablets: light blue, oval tablets with "AL" marking, a score line, and "1.0" on one side, and "G" on the other side.
Alpragen is available in packaging containing 30 tablets in blisters.
For more detailed information, you should contact the marketing authorization holder or the parallel importer.
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
McDermott Laboratories LTD
trading as Gerard Laboratories
35/36 Baldoyle Industrial Estate, Grange Road, Dublin, Ireland
Mylan Hungary Kft.
2900 Komárom
Mylan utca 1.
Hungary
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Spanish marketing authorization number: 665208.4
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.